根据最新合作协议，Oxford Biomedica（OXB.UK）与制药巨头施贵宝（Bristol-Myers Squibb）达成战略合作框架。双方计划通过技术整合与产能协同，在2026年正式启动商业化生产阶段。
这一合作标志着Oxford Biomedica在细胞与基因治疗领域的制造能力获得重要认可。通过利用其先进的病毒载体平台技术，企业将为施贵宝的创新疗法提供规模化生产支持。该时间节点的设定既考虑了技术转移的复杂性，也兼顾了监管审批的预期进度。
此次协议不仅强化了Oxford Biomedica作为合同开发与生产组织（CDMO）的行业地位，更凸显了生物制药产业链上下游协同的发展趋势。随着基因治疗市场的快速扩张，具备尖端生产技术的企业将持续获得战略合作机遇。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.